Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antibodies, Monoclonal"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 100155

Starter badań:

Tytuł:
Toxicokinetics of a humanized anti-cocaine monoclonal antibody in male and female rats and lack of cross-reactivity.
Autorzy:
Webster RP; Department of Pharmacology & Systems Physiology, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Marckel JA; Department of Pharmacology & Systems Physiology, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Norman AB; Department of Pharmacology & Systems Physiology, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Pokaż więcej
Źródło:
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 15; Vol. 19 (3), pp. 2274222. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Cocaine*/toxicity
Cocaine*/metabolism
Animals ; Female ; Male ; Rats ; Antibodies, Monoclonal ; Cross Reactions ; Toxicokinetics
Czasopismo naukowe
Szczegóły
Tytuł:
Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
Autorzy:
Singh N; Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Staves J; Oxford University Hospitals, NHS Foundation Trust, Oxford, UK.
Storry JR; Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden.
Dinoso J; Gilead Sciences, Inc, Foster City, California, USA.
Renard C; Gilead Sciences, Inc, Foster City, California, USA.
Doshi P; Gilead Sciences, Inc, Foster City, California, USA.
Johnson LDS; Gilead Sciences, Inc, Foster City, California, USA.
Westhoff CM; New York Blood Center Enterprises, Immunohematology and Blood Group Genomics, New York, New York, USA.
Murphy MF; NHS Blood and Transplant, Oxford University Hospitals NHS Foundation Trust and the University of Oxford, Oxford, UK.
Pokaż więcej
Źródło:
Transfusion [Transfusion] 2023 Dec; Vol. 63 (12), pp. 2377-2383. Date of Electronic Publication: 2023 Nov 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Antineoplastic Agents*
Humans ; Antibodies, Monoclonal, Humanized ; Blood Transfusion ; CD47 Antigen
Czasopismo naukowe
Szczegóły
Tytuł:
Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab.
Autorzy:
Quiñonez-Alvarado MG; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Chávez-Hurtado P; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Caro-Palomera JC; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Niño-Trejo OL; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Jiménez-Dolores JI; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Muñoz-Villegas P; Regional Medical Affairs Department, Laboratorios Sophia S.A. de C.V, Paseo Del Norte 5255, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Baiza-Durán L; Regional Medical Affairs Department, Laboratorios Sophia S.A. de C.V, Paseo Del Norte 5255, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico.
Quintana-Hau JD; Research and Development Department, Centro de Investigación Sophia S.A. de C.V, Paseo Del Norte 4896, Guadalajara Technology Park, Zapopan, 45010, Jalisco, Mexico. Electronic address: .
Pokaż więcej
Źródło:
Biologicals : journal of the International Association of Biological Standardization [Biologicals] 2023 Nov; Vol. 84, pp. 101711. Date of Electronic Publication: 2023 Sep 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Vascular Endothelial Growth Factor A*/metabolism
Bevacizumab/pharmacology ; Glycosylation ; Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival.
Autorzy:
Miura S; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Cardiovascular Surgery, Sapporo Medical University, Sapporo, Japan; Department of Cardiovascular Surgery, Teine Keijinkai Hospital, Sapporo, Japan. Electronic address: .
Habibabady ZA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pollok F; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Anesthesiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Ma M; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rosales IA; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kinoshita K; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pratts S; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
McGrath G; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Chaban R; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Fogarty S; Tonix Pharmaceuticals, Chatham, New Jersey, USA.
Meibohm B; College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Daugherty B; Tonix Pharmaceuticals, Chatham, New Jersey, USA.
Lederman S; Tonix Pharmaceuticals, Chatham, New Jersey, USA.
Pierson RN 3rd; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: .
Pokaż więcej
Źródło:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2023 Aug; Vol. 23 (8), pp. 1182-1193. Date of Electronic Publication: 2023 Apr 07.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Graft Rejection*/etiology
Graft Rejection*/prevention & control
Animals ; CD40 Ligand ; Antibodies, Monoclonal, Humanized ; Isoantibodies ; Allografts ; Primates ; Graft Survival
Czasopismo naukowe
Szczegóły
Tytuł:
Avelumab in Patients With Metastatic Colorectal Cancer.
Autorzy:
Redman JM; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
O'Sullivan Coyne G; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Reed CT; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Madan RA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Strauss J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Steinberg SJ; Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Marté J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Cordes L; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Heery C; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Gulley JL; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Sep 07; Vol. 28 (9), pp. 823-e804.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Colorectal Neoplasms*/drug therapy
Humans ; Antibodies, Monoclonal/adverse effects ; Colonic Neoplasms ; Rectal Neoplasms ; Response Evaluation Criteria in Solid Tumors
Czasopismo naukowe
Szczegóły
Tytuł:
Limited excretion of dupilumab into breastmilk: A case report.
Autorzy:
Dekkers C; Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
El Amrani M; Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
van Luin M; Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Bakker D; Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
Plusjé L; Department of Dermatology, Red Cross Hospital Beverwijk, Beverwijk, The Netherlands.
van Wijk F; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
de Bruin-Weller M; Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Sep; Vol. 37 (9), pp. e1154-e1155. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Milk, Human*
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal
Raport
Szczegóły
Tytuł:
Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomised, double-blind, placebo-controlled Phase Ib study.
Autorzy:
Sinclair R; Sinclair Dermatology, East Melbourne, Victoria, Australia.
Sharifeh S; The Bridge Family Practice and Skin Clinic, Halls Head, Western Australia, Australia.
Thackwray S; University of Sunshine Coast, Sippy Downs, Queensland, Australia.
Lickliter J; Nucleus Network, Royal Brisbane Hospital, Herston, Queensland, Australia.
Wu J; Zai Lab (Shanghai) Co., Ltd., Shanghai, China.
Li J; Zai Lab (Shanghai) Co., Ltd., Shanghai, China.
Qi B; Zai Lab (Shanghai) Co., Ltd., Shanghai, China.
Bland-Ward P; Crescendo Biologics Ltd, Cambridge, UK.
Reinhart H; Zai Lab (Shanghai) Co., Ltd., Shanghai, China.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2023 Sep; Vol. 32 (9), pp. 1538-1545. Date of Electronic Publication: 2023 Jun 28.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*
Psoriasis*
Humans ; Antibodies, Monoclonal, Humanized ; Interleukin-17 ; Treatment Outcome ; Double-Blind Method ; Severity of Illness Index
Czasopismo naukowe
Szczegóły
Tytuł:
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.
Autorzy:
Shoji S; Pharmacometrics, Pfizer R&D Japan, Tokyo, Japan.
Suzuki A; Pharmacometrics, Pfizer R&D Japan, Tokyo, Japan.
Nouri P; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
Cai CH; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
Gaitonde P; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
Marshall S; Pharmacometrics, Pfizer R&D Ltd., Sandwich, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Sep; Vol. 12 (9), pp. 1358-1370. Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Nerve Growth Factor*
Humans ; Antibodies, Monoclonal, Humanized ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Autorzy:
Zhou J; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhong L; Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Chowdhury D; Gobind Ballabh Pant Institute of Post Graduate Medical Education and Research, New Delhi, India.
Skorobogatykh K; University Headache Clinic, Moscow, Russia.
Luo G; Stroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yang X; Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Zhang M; Department of Neurology, Chinese PLA General Hospital, Beijing, China.
Sun L; Eli Lilly and Company, Shanghai, China.
Liu H; Eli Lilly and Company, Shanghai, China.
Qian C; Eli Lilly and Company, Shanghai, China.
Yu S; Department of Neurology, Chinese PLA General Hospital, Beijing, China. .
Pokaż więcej
Źródło:
The journal of headache and pain [J Headache Pain] 2023 Aug 04; Vol. 24 (1), pp. 103. Date of Electronic Publication: 2023 Aug 04.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Migraine Disorders*/prevention & control
Humans ; Treatment Outcome ; Antibodies, Monoclonal, Humanized/therapeutic use ; Double-Blind Method
Czasopismo naukowe
Szczegóły
Tytuł:
Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
Autorzy:
Lobatón T; Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Truyens M; Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Aug; Vol. 58 (3), pp. 359-360.
Typ publikacji:
Editorial
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Colitis, Ulcerative*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized
Opinia redakcyjna
Szczegóły
Tytuł:
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain.
Autorzy:
Cruz VL; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Souza-Egipsy V; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Gion M; University Hospital Ramon y Cajal, 28304 Madrid, Spain.
Pérez-García J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, 08017 Barcelona, Spain.; Medical Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain.
Cortes J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, 08017 Barcelona, Spain.; Medical Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain.; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, 28108 Madrid, Spain.
Ramos J; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Vega JF; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 27; Vol. 24 (15). Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Receptor, ErbB-2*/metabolism
Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols ; Trastuzumab
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Further evidence for the long-term safety of guselkumab.
Autorzy:
Lloyd-Lavery A; Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Pokaż więcej
Źródło:
The British journal of dermatology [Br J Dermatol] 2023 Jul 07; Vol. 189 (1), pp. 10-11.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Psoriasis*/drug therapy
Humans ; Antibodies, Monoclonal/therapeutic use
Opinia redakcyjna
Szczegóły
Tytuł:
Effectiveness and safety of reduced-dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series.
Autorzy:
Hsieh CY; Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan.
Tsai TF; Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2023 Jul; Vol. 32 (7), pp. 1048-1050. Date of Electronic Publication: 2023 Apr 09.
Typ publikacji:
Letter
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Severity of Illness Index ; Retrospective Studies
Opinia redakcyjna
Szczegóły
Tytuł:
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
Autorzy:
Hwang M; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.
Fan C; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Yue MS; Certara, Princeton, New Jersey, USA.
Zhou D; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA.
Paturel C; Innate Pharma, Marseille, France.
Andre P; Innate Pharma, Marseille, France.
Cheng LY; Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Mitchell P; Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Kourtesis P; Early Clinical Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Ruscica D; Global Clinical Strategy, Oncology R&D, AstraZeneca, Cambridge, UK.
Das M; Early Clinical Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Morsli N; Global Clinical Strategy, Oncology R&D, AstraZeneca, Cambridge, UK.
Ren S; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Gibbs M; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA.
Phipps A; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Song X; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Pokaż więcej
Źródło:
Journal of clinical pharmacology [J Clin Pharmacol] 2023 Jul; Vol. 63 (7), pp. 817-829. Date of Electronic Publication: 2023 Apr 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/pharmacokinetics
Neoplasms*/drug therapy
Humans ; Antibodies, Monoclonal/pharmacokinetics ; Body Weight ; Models, Biological
Czasopismo naukowe
Szczegóły
Tytuł:
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
Autorzy:
Tang W; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA. .
Tummala R; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Almquist J; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Hwang M; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.
White WI; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
Boulton DW; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
MacDonald A; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Pokaż więcej
Źródło:
Clinical pharmacokinetics [Clin Pharmacokinet] 2023 May; Vol. 62 (5), pp. 655-671. Date of Electronic Publication: 2023 May 06.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/pharmacology
Antibodies, Monoclonal, Humanized*/therapeutic use
Lupus Erythematosus, Systemic*/drug therapy
Humans ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
T-cell lymphoma associated with dupilumab.
Autorzy:
Shimada M; Hematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan. .
Inano S; Hematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.
Kitano T; Hematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2023 Jun; Vol. 102 (6), pp. 1601-1602. Date of Electronic Publication: 2023 Apr 27.
Typ publikacji:
Letter
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Lymphoma, T-Cell*/drug therapy
Humans ; Antibodies, Monoclonal
Opinia redakcyjna
Szczegóły
Tytuł:
Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
Autorzy:
Liu W; Department of Ophthalmology, Ankang Hospital of Traditional Chinese Medicine, No. 47 Bashan East Rd., Hanbin Dist, Ankang City, 725000, China.
Bai D; Department of Ophthalmology, Ankang Hospital of Traditional Chinese Medicine, No. 47 Bashan East Rd., Hanbin Dist, Ankang City, 725000, China.; Wenzhou Medical University, Wenzhou, China.
Kou L; Department of Ophthalmology, Ankang Hospital of Traditional Chinese Medicine, No. 47 Bashan East Rd., Hanbin Dist, Ankang City, 725000, China. .
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2023 May 29; Vol. 23 (1), pp. 240. Date of Electronic Publication: 2023 May 29.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Uveitis*/drug therapy
Humans ; Adalimumab/therapeutic use ; Infliximab/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized ; Tumor Necrosis Factor-alpha ; Inflammation/drug therapy
Czasopismo naukowe
Szczegóły
Tytuł:
The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series.
Autorzy:
Zhou Q; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yin D; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ma J; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: .
Chen S; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China. Electronic address: .
Pokaż więcej
Źródło:
Journal of neuroimmunology [J Neuroimmunol] 2023 Apr 15; Vol. 377, pp. 578062. Date of Electronic Publication: 2023 Mar 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Autoimmune Diseases of the Nervous System*/drug therapy
Humans ; Antigens, CD20 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Rituximab
SCR Disease Name:
Hashimoto's encephalitis
Czasopismo naukowe
Szczegóły
Tytuł:
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
Autorzy:
Kubota T; Department of Paediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Namba N; Division of Paediatrics and Perinatology, Tottori University Faculty of Medicine, Tottori, Japan.
Tanaka H; Department of Paediatrics, Okayama Saiseikai General Hospital, Okayama, Japan.
Muroya K; Department of Endocrinology and Metabolism, Kanagawa Children's Medical Centre, Kanagawa, Japan.
Imanishi Y; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Takeuchi Y; Endocrine Centre, Toranomon Hospital, Tokyo, Japan.; Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Kanematsu M; Kyowa Kirin Co., Ltd., Oteomachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo, Japan. .
Sun W; Kyowa Kirin, Inc., 212 Carnegie Centre, Princeton, NJ, 08540, USA.
Seino Y; Department of Paediatrics, Osaka Hospital, Japan Community Healthcare Organisation, Osaka, Japan.
Ozono K; Department of Paediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Pokaż więcej
Źródło:
Advances in therapy [Adv Ther] 2023 Apr; Vol. 40 (4), pp. 1530-1545. Date of Electronic Publication: 2023 Jan 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/adverse effects
Familial Hypophosphatemic Rickets*/drug therapy
Humans ; Adult ; Child ; Antibodies, Monoclonal, Humanized/therapeutic use ; Phosphates/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
Autorzy:
Stiboy E; School of Public Health, The University of Sydney, Camperdown, Australia.
Chan M; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.
Islam MS; National Center for Epidemiology and Population Health, ANU, Canberra, Australia.
Saravanos GL; Chidlren's Hospital Westmead Clinical School, The University of Sydney, Camperdown, Australia.; Susan Wakil School of Nursing and Midwifery, The University of Sydney, Camperdown, Australia.
Lui K; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Australian and New Zealand Neonatal Network, UNSW, Sydney, Sydney, Australia.; Deaprtment of Newborn, The Royal Hospital for Women, Randwick, Australia.
Jaffe A; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Respiratory Department, The Sydney Children's Hospital, Randwick, Australia.
Homaira N; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Respiratory Department, The Sydney Children's Hospital, Randwick, Australia.
Pokaż więcej
Źródło:
Pediatric pulmonology [Pediatr Pulmonol] 2023 Apr; Vol. 58 (4), pp. 1210-1220. Date of Electronic Publication: 2023 Feb 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Respiratory Syncytial Virus Infections*/prevention & control
Respiratory Syncytial Virus Infections*/drug therapy
Child ; Humans ; Infant ; Infant, Newborn ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Australia ; Hospitalization ; Infant, Premature ; Palivizumab/therapeutic use ; Respiratory Syncytial Viruses ; Practice Guidelines as Topic
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 100155

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies